1
|
Stefaniak P, Kraziński BE, Kieżun J, Majewska H, Godlewski J. Altered immunoexpression of DNA polymerase delta 1 catalytic subunit (POLD1) in colorectal cancer. Contemp Oncol (Pozn) 2023; 27:147-154. [PMID: 38239863 PMCID: PMC10793622 DOI: 10.5114/wo.2023.133505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2023] [Accepted: 10/25/2023] [Indexed: 01/22/2024] Open
Abstract
Introduction The study aimed to determine the immunoexpression levels of polymerase delta 1 catalytic subunit (POLD1), a catalytic and proofreading subunit of DNA polymerase delta, in the sections of colorectal cancer (CRC), and to evaluate the significance of POLD1 as a potential prognostic factor in CRC. Material and methods Paired, tumour and non-cancerous tissue samples of the large intestine distant to the neoplasm were collected from the postoperative material of 78 patients who underwent surgical resection of CRC tumours. Polymerase delta 1 catalytic subunit protein levels were determined using immunohistochemistry. Clinical, pathomorphological, and survival data of the patients were pooled. In addition, POLD1 mRNA expression levels of 599 CRC patients were extracted from The Cancer Genome Atlas (TCGA) datasets and subjected to statistical and survival analysis including the Kaplan-Meier method followed by the log-rank test. Results Immunoexpression of POLD1 was found in the nuclei of the tumour cells and epithelial cells of unchanged intestinal mucosa. Polymerase delta 1 catalytic subunit immunoreactivity in the tumour was heterogenous, and the average immunoreactivity score was decreased in cancer cells when compared to the mucosa of matched sections of unchanged large intestine (p = 0.0259). However, POLD1 expression at the protein and mRNA levels did not associate with clinicopathological characteristics of the patients and their survival. Conclusions Despite previous studies suggesting that POLD1 genetic alterations could be promising molecular biomarkers in CRC, our results do not support any prognostic significance of POLD1 expression in CRC.
Collapse
Affiliation(s)
- Przemysław Stefaniak
- Surgical Oncology Clinic, Hospital Ministry of Internal Affairs with Warmia and Mazury Oncology Centre, Olsztyn, Poland
| | - Bartłomiej Emil Kraziński
- Department of Human Histology and Embryology, School of Medicine, University of Warmia and Mazury in Olsztyn, Poland
| | - Jacek Kieżun
- Department of Human Histology and Embryology, School of Medicine, University of Warmia and Mazury in Olsztyn, Poland
| | - Hanna Majewska
- Department of Pathomorphology and Forensic Medicine, School of Medicine, University of Warmia and Mazury in Olsztyn, Poland
| | - Janusz Godlewski
- Surgical Oncology Clinic, Hospital Ministry of Internal Affairs with Warmia and Mazury Oncology Centre, Olsztyn, Poland
- Department of Human Histology and Embryology, School of Medicine, University of Warmia and Mazury in Olsztyn, Poland
| |
Collapse
|
2
|
Baněčková M, Thompson LDR, Hyrcza MD, Vaněček T, Agaimy A, Laco J, Simpson RHW, Di Palma S, Stevens TM, Brcic L, Etebarian A, Dimnik K, Majewska H, Stárek I, O'Regan E, Salviato T, Helliwell T, Horáková M, Biernat W, Onyuma T, Michal M, Leivo I, Skalova A. Salivary Gland Secretory Carcinoma: Clinicopathologic and Genetic Characteristics of 215 Cases and Proposal for a Grading System. Am J Surg Pathol 2023; 47:661-677. [PMID: 37070739 DOI: 10.1097/pas.0000000000002043] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/19/2023]
Abstract
Salivary gland secretory carcinoma (SC), previously mammary analog SC, is a low-grade malignancy characterized by well-defined morphology and an immunohistochemical and genetic profile identical to SC of the breast. Translocation t(12;15)(p13;q25) resulting in the ETV6 :: NTRK3 gene fusion is a characteristic feature of SC along with S100 protein and mammaglobin immunopositivity. The spectrum of genetic alterations for SC continues to evolve. The aim of this retrospective study was to collect data of salivary gland SCs and to correlate their histologic, immunohistochemical, and molecular genetic data with clinical behavior and long-term follow-up. In this large retrospective study, we aimed to establish a histologic grading scheme and scoring system. A total of 215 cases of salivary gland SCs diagnosed between 1994 and 2021 were obtained from the tumor registries of the authors. Eighty cases were originally diagnosed as something other than SC, most frequently acinic cell carcinoma. Lymph node metastases were identified in 17.1% (20/117 cases with available data), with distant metastasis in 5.1% (6/117). Disease recurrence was seen in 15% (n=17/113 cases with available data). The molecular genetic profile showed ETV6 :: NTRK3 gene fusion in 95.4%, including 1 case with a dual fusion of ETV6 :: NTRK3 and MYB :: SMR3B . Less frequent fusion transcripts included ETV6 :: RET (n=12) and VIM :: RET (n=1). A 3-tiered grading scheme using 6 pathologic parameters (prevailing architecture, pleomorphism, tumor necrosis, perineural invasion (PNI), lymphovascular invasion (LVI), and mitotic count and/or Ki-67 labeling index) was applied. Grade 1 histology was observed in 44.7% (n=96), grade 2 in 41.9% (n=90), and grade 3 in 13.5% (n=29) of cases. Compared with low-grade and intermediate-grade SC, high-grade tumors were associated with a solid architecture, more prominent hyalinization, infiltrative tumor borders, nuclear pleomorphism, presence of PNI and/or LVI, and Ki-67 proliferative index >30%. High-grade transformation, a subset of grade 2 or 3 tumors, seen in 8.8% (n=19), was defined as an abrupt transformation of conventional SC into high-grade morphology, sheet-like growth, and a tumor lacking distinctive features of SC. Both overall survival and disease-free survival (5 and 10 y) were negatively affected by tumor grade, stage, and TNM status (each P <0.0001). SC is a low-grade malignancy with predominantly solid-microcystic growth patterns, driven by a gene fusion, most commonly ETV6 :: NTRK3 . There is a low risk for local recurrence and a good overall long-term survival, with a low risk for distant metastasis but a higher risk for locoregional lymph node metastasis. The presence of tumor necrosis, hyalinization, PNI and/or LVI, and positive resection margins correlate with higher tumor grade, less favorable prognosis, and increased mortality. The statistical results allowed us to design a 3-tiered grading system for salivary SC.
Collapse
Affiliation(s)
- Martina Baněčková
- Department of Pathology, Charles University, Faculty of Medicine in Plzen
- Bioptic Laboratory Ltd Plzen
| | | | - Martin D Hyrcza
- Department of Pathology and Laboratory Medicine, University of Calgary, Arnie Charbonneau Cancer Institute
| | - Tomáš Vaněček
- Molecular Genetic Laboratory, Bioptic Laboratory Ltd, Plzen
| | - Abbas Agaimy
- Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Comprehensive Cancer Center (CCC) Erlangen-EMN, Erlangen, Germany
| | - Jan Laco
- The Fingerland Department of Pathology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove
| | - Roderick H W Simpson
- Department of Pathology and Laboratory Medicine, University of Calgary, Calgary Laboratory Services, Foothills Medical Centre, Calgary, AB, Canada
| | - Silvana Di Palma
- Division of Clinical Medicine, Department of Histopathology, University of Surrey, Royal Surrey County Hospital, Guildford, Surrey
| | - Todd M Stevens
- Department of Pathology, University of Alabama at Birmingham, Birmingham, AL
| | - Luka Brcic
- Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria
| | - Arghavan Etebarian
- Department of Oral and Maxillofacial Pathology, School of Dentistry, Alborz University of Medical Sciences, Karaj, Iran
| | - Katarina Dimnik
- Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
| | - Hanna Majewska
- Department of Pathology, Warmia and Mazury University, Olsztyn
| | - Ivo Stárek
- Department of Otorhinolaryngology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
| | - Esther O'Regan
- Department of Histopathology, St. James's Hospital & Dublin Dental Hospital, Trinity College Dublin, Dublin, Ireland
| | - Tiziana Salviato
- Division of Pathology, Department of Medical and Surgical Sciences for Children & Adults, University-Hospital of Modena and Reggio Emilia, Modena, Italy
| | - Tim Helliwell
- Department of Cellular Pathology, University of Liverpool, Liverpool, UK
| | - Markéta Horáková
- Department of Pathology, Charles University, Faculty of Medicine in Plzen
- Bioptic Laboratory Ltd Plzen
| | - Wojciech Biernat
- Department of Pathology, Medical University of Gdansk, Gdansk, Poland
| | - Timothy Onyuma
- Department of Pathology, Kenyatta National Hospital, Nairobi, Kenya
| | - Michal Michal
- Department of Pathology, Charles University, Faculty of Medicine in Plzen
- Bioptic Laboratory Ltd Plzen
| | - Ilmo Leivo
- Institute of Biomedicine, Pathology, University of Turku and Turku University Hospital, Turku, Finland
| | - Alena Skalova
- Department of Pathology, Charles University, Faculty of Medicine in Plzen
- Bioptic Laboratory Ltd Plzen
| |
Collapse
|
3
|
Skálová A, Agaimy A, Vanecek T, Baněčková M, Laco J, Ptáková N, Šteiner P, Majewska H, Biernat W, Corcione L, Eis V, Koshyk O, Vondrák J, Michal M, Leivo I. Molecular Profiling of Clear Cell Myoepithelial Carcinoma of Salivary Glands With EWSR1 Rearrangement Identifies Frequent PLAG1 Gene Fusions But No EWSR1 Fusion Transcripts. Am J Surg Pathol 2021; 45:1-13. [PMID: 33027073 DOI: 10.1097/pas.0000000000001591] [Citation(s) in RCA: 37] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Myoepithelial carcinoma of salivary glands is an underrecognized and challenging entity with a broad morphologic spectrum, including an EWSR1-rearranged clear cell variant. Myoepithelial carcinoma is generally aggressive with largely unknown genetic features. A retrospective review of Salivary Gland Tumor Registry in Pilsen searching for the key words "clear cell myoepithelial carcinoma," "hyalinizing clear cell," and "clear cell malignant myoepithelioma" yielded 94 clear cell myoepithelial carcinomas (CCMCs) for molecular analysis of EWSR1 rearrangement using fluorescence in situ hybridization (FISH). Tumors positive for EWSR1 gene rearrangement were tested by next-generation sequencing (NGS) using fusion-detecting panels. NGS results were confirmed by reverse-transcription polymerase chain reaction or by FISH. Twenty-six tumors originally diagnosed as CCMC (26/94, 27.6%) revealed split signals for EWSR1 by FISH. Six of these tumors (6/26, 23%) displayed amplification of the EWSR1 locus. Fifteen cases were analyzable by NGS, whereas 9 were not, and tissue was not available in 2 cases. None of the CCMCs with EWSR1 rearrangements detected by FISH had an EWSR1 fusion transcript. Fusion transcripts were detected in 6 cases (6/15, 40%), including LIFR-PLAG1 and CTNNB1-PLAG1, in 2 cases each, and CHCHD7-PLAG1 and EWSR1-ATF1 fusions were identified in 1 case each. Seven cases, including those with PLAG1 fusion, were positive for PLAG1 rearrangement by FISH, with notable exception of CHCHD7-PLAG1, which is an inversion not detectable by FISH. One single case with EWSR1-ATF1 fusion in NGS showed ATF1 gene rearrangement by FISH and was reclassified as clear cell carcinoma (CCC). In addition, another 4 cases revealed ATF1 rearrangement by FISH and were reclassified as CCC as well. Moreover, 12/68 (17%) CCMCs with intact EWSR1 gene were selected randomly and analyzed by NGS. PLAG1 fusions were found in 5 cases (5/12, 41.6%) with LIFR (2 cases), FGFR1 (2 cases), and CTNNB1 (1 case) as partner genes. Overall, PLAG1 gene rearrangements were detected in 10/38 (26%) tested cases. None of the tumors had SMARCB1 loss by immunohistochemistry as a possible explanation for the EWSR1 abnormalities in FISH. Novel findings in our NGS study suggest that EWSR1-FISH positive CCMC is a gene fusion-driven disease with frequent oncogenic PLAG1 fusions, including LIFR-PLAG1 and CTNNB1-PLAG1 in most cases. Productive EWSR1 fusions are found only in a minority of EWSR1-ATF1-rearranged cases, which were in part reclassifiable as CCCs. Detectable EWSR1-FISH abnormality in CCMCs without gene fusion perhaps represents a passenger mutation with minor or no oncologic effect.
Collapse
Affiliation(s)
- Alena Skálová
- Department of Pathology, Faculty of Medicine in Pilsen, Charles University
- Bioptic Laboratory Ltd
| | - Abbas Agaimy
- Department of Pathology, Friedrich-Alexander University Erlangen-Nürnberg (FAU), University Hospital of Erlangen, Erlangen, Germany
| | - Tomas Vanecek
- Molecular and Genetic Laboratory, Bioptic Laboratory Ltd, Pilsen
| | - Martina Baněčková
- Department of Pathology, Faculty of Medicine in Pilsen, Charles University
- Bioptic Laboratory Ltd
| | - Jan Laco
- The Fingerland Department of Pathology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove
| | - Nikola Ptáková
- Molecular and Genetic Laboratory, Bioptic Laboratory Ltd, Pilsen
| | - Petr Šteiner
- Molecular and Genetic Laboratory, Bioptic Laboratory Ltd, Pilsen
| | - Hanna Majewska
- Department of Pathology, Warmia nad Mazury University, Olsztyn
| | - Wojciech Biernat
- Department of Pathology, Medical University of Gdansk, Gdansk, Poland
| | - Luigi Corcione
- Department of Pathology, University of Parma, Parma, Italy
| | - Václav Eis
- Department of Pathology, 3rd Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague
| | | | - Jan Vondrák
- Molecular and Genetic Laboratory, South Bohemian University, Ceske Budejovice, Czech Republic
| | - Michal Michal
- Department of Pathology, Faculty of Medicine in Pilsen, Charles University
| | - Ilmo Leivo
- Institute of Biomedicine, University of Turku
- Department of Pathology, Turku University Hospital, Turku, Finland
| |
Collapse
|
4
|
Smolle MA, Czapiewski P, Lapińska-Szumczyk S, Majewska H, Supernat A, Zaczek A, Biernat W, Golob-Schwarzl N, Haybaeck J. The Prognostic Significance of Eukaryotic Translation Initiation Factors (eIFs) in Endometrial Cancer. Int J Mol Sci 2019; 20:ijms20246169. [PMID: 31817792 PMCID: PMC6941158 DOI: 10.3390/ijms20246169] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2019] [Revised: 12/01/2019] [Accepted: 12/05/2019] [Indexed: 02/07/2023] Open
Abstract
Whilst the role of eukaryotic translation initiation factors (eIFs) has already been investigated in several human cancers, their role in endometrial cancer (EC) is relatively unknown. In the present retrospective study, 279 patients with EC (1180 samples) were included (mean age: 63.0 years, mean follow-up: 6.1 years). Samples were analysed for expression of 7 eIFs subunits (eIF2α, eIF3c, eIF3h, eIF4e, eIF4g, eIF5, eIF6) through immunohistochemistry and western blotting. Fifteen samples of healthy endometrium served as controls. Density and intensity were assessed and mean combined scores (CS) calculated for each patient. Upon immunohistochemistry, median eIF5 CS were significantly higher in EC as compared with non-neoplastic tissue (NNT, p < 0.001), whilst median eIF6 CS were significantly lower in EC (p < 0.001). Moreover, eIF5 (p = 0.002), eIF6 (p = 0.032) and eIF4g CS (p = 0.014) were significantly different when comparing NNT with EC grading types. Median eIF4g CS was higher in type II EC (p = 0.034). Upon western blot analysis, eIF4g (p < 0.001), peIF2α (p < 0.001) and eIF3h (p < 0.05) were significantly overexpressed in EC, while expression of eIF3c was significantly reduced in EC as compared with NNT (p < 0.001). The remaining eIFs were non-significant. Besides tumour stage (p < 0.001) and patient’s age (p < 0.001), high eIF4g CS-levels were independently associated with poor prognosis (HR: 1.604, 95%CI: 1.037–2.483, p = 0.034). The other eIFs had no prognostic significance. Notably, the independent prognostic significance of eIF4g was lost when adding tumour type. Considering the difficulties in differentiating EC type I and II, eIF4g may serve as a novel prognostic marker indicating patient outcome.
Collapse
Affiliation(s)
- Maria Anna Smolle
- Department of Orthopaedics and Trauma, Medical University of Graz, Auenbruggerplatz 5, 8036 Graz, Austria;
- Area 2 Cancer, Center for Biomarker Research in Medicine, Stiftingtalstraße 5, 8010 Graz, Austria;
| | - Piotr Czapiewski
- Department of Pathomorphology, Medical University of Gdansk, Mariana Smoluchowskiego 17, 80-214 Gdańsk, Poland; (P.C.); (H.M.); (W.B.)
- Department of Pathology, Medical Faculty, Otto-von-Guericke University Magdeburg, Leipziger Straße 44, 39120 Magdeburg, Germany
| | - Sylwia Lapińska-Szumczyk
- Department of Gynaecology, Gynaecological Oncology and Gynaecological Endocrinology, Medical University of Gdańsk, M. Skłodowskiej-Curie 3a Street, 80-210 Gdańsk, Poland;
| | - Hanna Majewska
- Department of Pathomorphology, Medical University of Gdansk, Mariana Smoluchowskiego 17, 80-214 Gdańsk, Poland; (P.C.); (H.M.); (W.B.)
| | - Anna Supernat
- Department of Medical Biotechnology, Intercollegiate Faculty of Biotechnology, University of Gdańnsk and Medical University of Gdańsk, Bażyńskiego 1a, 80-952 Gdańsk, Poland; (A.S.); (A.Z.)
| | - Anna Zaczek
- Department of Medical Biotechnology, Intercollegiate Faculty of Biotechnology, University of Gdańnsk and Medical University of Gdańsk, Bażyńskiego 1a, 80-952 Gdańsk, Poland; (A.S.); (A.Z.)
| | - Wojciech Biernat
- Department of Pathomorphology, Medical University of Gdansk, Mariana Smoluchowskiego 17, 80-214 Gdańsk, Poland; (P.C.); (H.M.); (W.B.)
| | - Nicole Golob-Schwarzl
- Area 2 Cancer, Center for Biomarker Research in Medicine, Stiftingtalstraße 5, 8010 Graz, Austria;
- Institute of Pathology, Medical University of Graz, Auenbruggerplatz 25, 8036 Graz, Austria
| | - Johannes Haybaeck
- Area 2 Cancer, Center for Biomarker Research in Medicine, Stiftingtalstraße 5, 8010 Graz, Austria;
- Department of Pathology, Medical Faculty, Otto-von-Guericke University Magdeburg, Leipziger Straße 44, 39120 Magdeburg, Germany
- Institute of Pathology, Medical University of Graz, Auenbruggerplatz 25, 8036 Graz, Austria
- Department of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Müllerstraße 44, 6020 Innsbruck, Austria
- Correspondence: ; Tel.: +49-391-67-15817
| |
Collapse
|
5
|
Clarke EL, Lauder AP, Hofstaedter CE, Hwang Y, Fitzgerald AS, Imai I, Biernat W, Rękawiecki B, Majewska H, Dubaniewicz A, Litzky LA, Feldman MD, Bittinger K, Rossman MD, Patterson KC, Bushman FD, Collman RG. Microbial Lineages in Sarcoidosis. A Metagenomic Analysis Tailored for Low-Microbial Content Samples. Am J Respir Crit Care Med 2019; 197:225-234. [PMID: 28846439 DOI: 10.1164/rccm.201705-0891oc] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
RATIONALE The etiology of sarcoidosis is unknown, but microbial agents are suspected as triggers. OBJECTIVES We sought to identify bacterial, fungal, or viral lineages in specimens from patients with sarcoidosis enriched relative to control subjects using metagenomic DNA sequencing. Because DNA from environmental contamination contributes disproportionately to samples with low authentic microbial content, we developed improved methods for filtering environmental contamination. METHODS We analyzed specimens from subjects with sarcoidosis (n = 93), control subjects without sarcoidosis (n = 72), and various environmental controls (n = 150). Sarcoidosis specimens consisted of two independent sets of formalin-fixed, paraffin-embedded lymph node biopsies, BAL, Kveim reagent, and fresh granulomatous spleen from a patient with sarcoidosis. All specimens were analyzed by bacterial 16S and fungal internal transcribed spacer ribosomal RNA gene sequencing. In addition, BAL was analyzed by shotgun sequencing of fractions enriched for viral particles, and Kveim and spleen were subjected to whole-genome shotgun sequencing. MEASUREMENTS AND MAIN RESULTS In one tissue set, fungi in the Cladosporiaceae family were enriched in sarcoidosis compared with nonsarcoidosis tissues; in the other tissue set, we detected enrichment of several bacterial lineages in sarcoidosis but not Cladosporiaceae. BAL showed limited enrichment of Aspergillus fungi. Several microbial lineages were detected in Kveim and spleen, including Cladosporium. No microbial lineage was enriched in more than one sample type after correction for multiple comparisons. CONCLUSIONS Metagenomic sequencing revealed enrichment of microbes in single types of sarcoidosis samples but limited concordance across sample types. Statistical analysis accounting for environmental contamination was essential to avoiding false positives.
Collapse
Affiliation(s)
| | | | - Casey E Hofstaedter
- 2 Division of Gastroenterology, Hepatology, and Nutrition, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; and
| | | | | | | | | | | | | | - Anna Dubaniewicz
- 5 Department of Pulmonology, Medical University of Gdansk, Gdansk, Poland
| | - Leslie A Litzky
- 6 Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
| | - Michael D Feldman
- 6 Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
| | - Kyle Bittinger
- 2 Division of Gastroenterology, Hepatology, and Nutrition, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; and
| | | | | | | | | |
Collapse
|
6
|
Markiewicz A, Nagel A, Szade J, Majewska H, Skokowski J, Seroczynska B, Stokowy T, Welnicka-Jaskiewicz M, Zaczek AJ. Aggressive Phenotype of Cells Disseminated via Hematogenous and Lymphatic Route in Breast Cancer Patients. Transl Oncol 2018; 11:722-731. [PMID: 29660692 PMCID: PMC6056759 DOI: 10.1016/j.tranon.2018.03.006] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2018] [Revised: 03/13/2018] [Accepted: 03/13/2018] [Indexed: 12/28/2022] Open
Abstract
Intratumoral heterogeneity of breast cancer remains a major challenge in successful treatment. Failure of cancer therapies can also be accredited to inability to systemically eradicate cancer stem cells (CSCs). Recent evidence points to the role of epithelial-mesenchymal transition (EMT) in expanding the pool of tumor cells with CSCs features. Thus, we assessed expression level as well as heterogeneity of CSCs markers in primary tumors (PT), lymph node metastasis (LNM), and circulating tumor cells (CTCs)-enriched blood fractions in order to correlate them with signs of EMT activation as well as clinicopathological data of breast cancer patients. Level of CSCs markers (ALDH1, CD44, CD133, OCT-4, NANOG) and EMT markers was quantified in PT (N=107), LNM (N=56), and CTCs-enriched blood fractions (N=85). Heterogeneity of CSCs markers expression within each PT and LNM was assessed by calculating Gini Index. Percentage of ALDH1-positive cells was elevated in PT in comparison to LNM (P = .005). However, heterogeneity of the four CSCs markers: ALDH1 (P = .019), CD133 (P = .009), OCT-4 (P = .027), and CD44 (P < .001) was decreased in LNM. Samples classified as mesenchymal (post-EMT) showed elevated expression of CSCs markers (OCT-4 and CD44 in PT; OCT-4 in LNM; ALDH1, OCT-4, NANOG, CD44 in CTCs). Patients with mesenchymal-like CTCs had worse prognosis than patients with epithelial-like or no CTCs (P = .0025). CSCs markers are enriched in PT, LNM, and CTCs with mesenchymal features, but their heterogeneity is decreased in metastatic lymph nodes. Mesenchymal CTCs phenotype correlates with poor prognosis of the patients.
Collapse
Affiliation(s)
- Aleksandra Markiewicz
- Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Poland.
| | - Anna Nagel
- Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Poland.
| | - Jolanta Szade
- Department of Pathology, Medical University of Gdansk, Poland.
| | - Hanna Majewska
- Department of Pathology, Medical University of Gdansk, Poland.
| | | | - Barbara Seroczynska
- Department of Medical Laboratory Diagnostics and Bank of Frozen Tissues and Genetic Specimens, Medical University of Gdansk, Poland.
| | - Tomasz Stokowy
- Department of Clinical Science, University of Bergen, Norway.
| | | | - Anna J Zaczek
- Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Poland.
| |
Collapse
|
7
|
Nagel A, Markiewicz A, Szade J, Majewska H, Skokowski J, Seroczynska B, Welnicka-Jaskiewicz M, Zaczek A. Expression of stem cell and mesenchymal markers in circulating tumor cells is associated with poor prognosis of early breast cancer patients. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx510.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
8
|
Stodulski D, Mikaszewski B, Majewska H, Wiśniewski P, Stankiewicz C. Probability and pattern of occult cervical lymph node metastases in primary parotid carcinoma. Eur Arch Otorhinolaryngol 2016; 274:1659-1664. [PMID: 27896425 PMCID: PMC5309280 DOI: 10.1007/s00405-016-4407-5] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2016] [Accepted: 11/24/2016] [Indexed: 11/27/2022]
Abstract
The present study was undertaken to evaluate real probability and pattern of cervical occult lymph node metastases (OLNM) in primary parotid carcinoma (PPC). We carried out a retrospective analysis of 66 patients treated in years 1992-2010 due to PPC, who underwent elective neck dissection (END). In search of risk factors for OLNM, we analysed the following parameters: age, sex, pT-Status, tumour size, skin invasion, facial nerve palsy, tumour fixation, extraparotid extension, localization, grade, histology, intra/periparotid LN metastases (IPLNM). OLNM was observed in 30.3% of patients. In a univariate analysis statistical significance was found for IPLNM, extraparotid extension and high risk histology. A multivariate analysis showed statistical significance only for the first variable. The most common location of cervical OLNM was level II (80%), then III (45%) and V (30%). In a compilation of our own material with data from the literature (5 series), we obtained a group of 80 patients with OLNM, selected out of 650 patients with cN0 (12.3%). The proportion of metastases to particular levels was the following: 69%-II, 22.5%-III, 20%-I,16%-V, 7.5%-IV. END should be carried out in case of all T3/T4a carcinomas with minimal range of levels II and III. Removal of levels Ib and Va is recommended as well. In the T1/T2 carcinomas with high grade/high risk histology, END should be performed including levels II and III.
Collapse
Affiliation(s)
- Dominik Stodulski
- Department of Otolaryngology, Medical University of Gdańsk, Gdańsk, Poland.
| | | | - Hanna Majewska
- Department of Pathomorphology, Medical University of Gdańsk, Gdańsk, Poland
| | - Piotr Wiśniewski
- Department of Endocrinology and Internal Medicine, Medical University of Gdańsk, Gdańsk, Poland
| | | |
Collapse
|
9
|
Łapińska-Szumczyk SM, Supernat AM, Żaczek AJ, Majewska H, Gulczyński J, Sawicki S, Biernat W, Wydra D. Rak błony śluzowej trzonu macicy u chorych po przebytej chorobie nowotworowej - aspekty kliniczne i molekularne. Ginekol Pol 2016; 87:88-93. [PMID: 27306283 DOI: 10.17772/gp/60559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2016] [Indexed: 11/12/2022] Open
Affiliation(s)
- Sylwia Maria Łapińska-Szumczyk
- Katedra i Klinika Ginekologii, Ginekologii Onkologicznej i Endokrynologii Ginekologicznej Gdańskiego Uniwersytetu Medycznego, Kliniczna 1a, 80-402 Gdańsk, Polska.
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Skálová A, Vanecek T, Simpson RHW, Laco J, Majewska H, Baneckova M, Steiner P, Michal M. Mammary Analogue Secretory Carcinoma of Salivary Glands: Molecular Analysis of 25 ETV6 Gene Rearranged Tumors With Lack of Detection of Classical ETV6-NTRK3 Fusion Transcript by Standard RT-PCR: Report of 4 Cases Harboring ETV6-X Gene Fusion. Am J Surg Pathol 2016; 40:3-13. [PMID: 26492182 DOI: 10.1097/pas.0000000000000537] [Citation(s) in RCA: 142] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
ETV6 gene abnormalities are well described in tumor pathology. Many fusion partners of ETV6 have been reported in a variety of epithelial and hematological malignancies. In salivary gland tumor pathology, however, the ETV6-NTRK3 translocation is specific for mammary analogue secretory carcinoma (MASC), and has not been documented in any other salivary tumor type. The present study comprised a clinical and molecular analysis of 25 cases morphologically and immunohistochemically typical of MASC. They all also displayed the ETV6 rearrangement as visualized by fluorescent in situ hybridization but lacked the classical ETV6-NTRK3 fusion transcript by standard reverse-transcriptase-polymerase chain reaction. In 4 cases, the classical fusion transcript was found by more sensitive, nested reverse-transcription-polymerase chain reaction. Five other cases harbored atypical fusion transcripts as detected by both standard and nested reverse-transcription-polymerase chain reaction. In addition, fluorescent in situ hybridization with an NTRK3 break-apart probe was also performed; rearrangement of NTRK3 gene was detected in 16 of 25 cases. In 3 other cases, the tissue was not analyzable, and in 2 further cases analysis could not be performed because of a lack of appropriate tissue material. Finally, in the 4 remaining cases whose profile was NTRK3 split-negative and ETV6 split-positive, unknown (non-NTRK) genes appeared to fuse with ETV6 (ETV6-X fusion). In looking for possible fusion partners, analysis of rearrangement of other kinase genes known to fuse with ETV6 was also performed, but without positive results. Although numbers were small, correlating the clinico-pathologic features of the 4 ETV6-X fusion tumors and 5 MASC cases with atypical fusion transcripts raises the possibility of that they may behave more aggressively.
Collapse
Affiliation(s)
- Alena Skálová
- *Department of Pathology, Faculty of Medicine in Plzen, Charles University, Prague †Bioptic Laboratory Ltd ‡Bioptic Laboratory Ltd, Molecular Pathology Laboratory, Plzen ∥The Fingerland Department of Pathology, Charles University in Prague, Faculty of Medicine and University Hospital, Hradec Kralove, Czech Republic §Department of Anatomical Pathology, University of Calgary and Foothills Medical Centre, Calgary, AB, Canada ¶Department of Pathology, Medical University of Gdansk, Gdansk, Poland
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Winczura P, Sosińska-Mielcarek K, Duchnowska R, Badzio A, Lakomy J, Majewska H, Pęksa R, Pieczyńska B, Radecka B, Dębska-Szmich S, Adamowicz K, Biernat W, Jassem J. Immunohistochemical Predictors of Bone Metastases in Breast Cancer Patients. Pathol Oncol Res 2015; 21:1229-36. [PMID: 26062800 PMCID: PMC4550640 DOI: 10.1007/s12253-015-9957-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/16/2015] [Accepted: 05/26/2015] [Indexed: 11/22/2022]
Abstract
Bones are the most common metastatic site of relapse in breast cancer patients and the prediction of bone metastases (BM) risk might prompt developing preventive and therapeutic strategies. The aim of the study was to correlate imumohistochemical (IHC) expression of selected proteins in primary breast cancer with the occurrence of BM. We analyzed expression of proteins potentially associated with BM in primary tumors of 184 patients with metastatic breast cancer (113 with- and 71 without BM). Expression of estrogen receptor (ER) in primary tumor was more common in patients with- compared to those without BM (74 vs. 45 % respectively, p = 0.0001), whereas in this subset less common was expression of parathyroid hormone related protein receptor type 1 (16 vs. 34 %, respectively, p = 0.007) and cytoplasmic expression of osteopontin (OPNcyt; 1.9 vs. 14 %, respectively, p = 0.002). The relationship between expression of ER and OPNcyt and the occurrence of BM was confirmed in the multivariate analysis. The ER-positive/OPNcyt negative phenotype was significantly more common in patients with- compared to those without BM (75 and 25 %, p < 0.0001, respectively; HR 1.79, p = 0.013). Luminal A (43 vs. 23 % respectively, p = 0.009) and luminal B/HER2-positive (16 vs. 4.9 % respectively, p = 0.032) subtypes were more common in patients with- compared to those without BM, whereas triple negative breast cancer subtype was less common (16 vs. 38 %, p = 0.002).
Collapse
|
12
|
Majewska H, Skálová A, Stodulski D, Klimková A, Steiner P, Stankiewicz C, Biernat W. Mammary analogue secretory carcinoma of salivary glands: a new entity associated with ETV6 gene rearrangement. Virchows Arch 2015; 466:245-54. [PMID: 25503077 PMCID: PMC4353861 DOI: 10.1007/s00428-014-1701-8] [Citation(s) in RCA: 108] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2014] [Revised: 11/04/2014] [Accepted: 11/28/2014] [Indexed: 11/29/2022]
Abstract
Mammary analogue secretory carcinoma (MASC) is a recently described salivary gland tumour that harbours the recurrent ETV6-NTRK3 translocation. This is the first series of MASC cases identified in the historic cohort of carcinomas of salivary glands with clinical/pathological correlation and follow-up data. We reviewed 183 primary carcinomas of major and minor salivary glands resected at the Medical University of Gdańsk, Poland, between 1992 and 2012. Based on morphology and immunohistochemistry, cases suspicious for MASC were selected, and the diagnosis was confirmed by fluorescence in situ hybridization (FISH) for ETV6 rearrangement and by RT-PCR for the ETV6-NTRK3 fusion transcript. Seven carcinomas met the criteria of MASC, as they exhibited a typical appearance with solid/microcystic and papillary architecture and intraluminal secretions, and cells completely devoid of basophilic cytoplasmic zymogen granules indicative of true acinar differentiation. The only paediatric case was an unencapsulated tumour composed of macrocystic structures covered by a mostly single but, focally, double layer of cells with apocrine morphology. In all cases, the neoplastic cells revealed immunoreactivity for S100, mammaglobin, cytokeratin CK7, CK8, STAT5a and vimentin. FISH for ETV6 gene rearrangement was positive in six out of seven cases, and RT-PCR was positive in three cases. MASC is a new entity of malignant epithelial salivary gland tumours not included in the 2005 WHO Classification of Head and Neck Tumours. There is a growing body of evidence that it is not as rare as was assumed, as is also indicated by our series (3.8 %). In most cases, MASC shares some microscopic features with AciCC, adenocarcinoma/cystadenocarcinoma NOS and low-grade MEC. In rare cases, MASC with high-grade transformation may mimic the morphological appearances of high-grade salivary gland malignancies, such as salivary duct carcinoma.
Collapse
Affiliation(s)
- Hanna Majewska
- Department of Pathomorphology, Medical University of Gdańsk, Gdańsk, Poland,
| | | | | | | | | | | | | |
Collapse
|
13
|
Markiewicz A, Wełnicka-Jaśkiewicz M, Seroczyńska B, Skokowski J, Majewska H, Szade J, Żaczek AJ. Epithelial-mesenchymal transition markers in lymph node metastases and primary breast tumors - relation to dissemination and proliferation. Am J Transl Res 2014; 6:793-808. [PMID: 25628790 PMCID: PMC4297347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2014] [Accepted: 10/15/2014] [Indexed: 06/04/2023]
Abstract
Epithelial-mesenchymal transition (EMT) was shown to enhance metastatic abilities of cancer cells, but it remains elusive in clinical samples. Moreover, EMT is rarely studied in lymph node metastases (LNM), thus limiting our understanding of its role outside of the primary tumors (PT). We collected a set of samples including triplets - PT, circulating tumor cells (CTCs)-enriched blood samples and LNM from 108 early breast cancer patients. With immunohistochemistry we analyzed levels of EMT effectors - E-cadherin, vimentin and N-cadherin in LNM, central areas and margins of PT. Additionally, expression of EMT core regulators TWIST1, SNAI1, SNAI2 was measured with RT-qPCR. Patients with E-cadherin loss had CTCs in 45% of the cases in comparison to 23% with normal E-cadherin level (P = 0.05). Mesenchymal phenotype of CTCs-enriched blood fractions was five-times more frequent in patients with E-cadherin loss in PT compared to PT with normal E-cadherin levels (P = 0.01). Epithelial/mesenchymal status of matched samples at different stages of dissemination was frequently discordant, especially for pairs involving CTCs, indicating high plasticity of tumor cells. LNM showed increased expression of TWIST1, SNAI1, SNAI2 accompanied by decreased Ki67 labeling index, with median Ki67 of 15% in PT and 10% in LNM (P = 0.0002). Our findings demonstrate that E-cadherin loss, not only in PT margin, might lead to seeding of especially malignant CTCs with mesenchymal phenotype. In comparison to PT, cells in LNM re-express E-cadherin, upregulate EMT transcription factors and reduce cell division rate, which could be viewed as their long-term survival strategy.
Collapse
Affiliation(s)
- Aleksandra Markiewicz
- Department of Medical Biotechnology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of GdańskDębinki 1 St, 80-211 Gdańsk, Poland
- Postgraduate School of Molecular Medicine, Medical University of WarsawŻwirki i Wigury 61 St, 02-091 Warsaw, Poland
| | | | - Barbara Seroczyńska
- Bank of Frozen Tissues and Genetic Specimens, Department of Medical Laboratory Diagnostics, Medical University of GdańskDębinki 7 St, 80-211 Gdańsk, Poland
| | - Jarosław Skokowski
- Bank of Frozen Tissues and Genetic Specimens, Department of Medical Laboratory Diagnostics, Medical University of GdańskDębinki 7 St, 80-211 Gdańsk, Poland
- Department of Surgical Oncology, Medical University of GdańskM. Smoluchowskiego 17 St, 80-214 Gdańsk, Poland
| | - Hanna Majewska
- Department of Pathomorphology, Medical University of GdańskM. Smoluchowskiego 17 St, 80-214 Gdańsk, Poland
| | - Jolanta Szade
- Department of Pathomorphology, Medical University of GdańskM. Smoluchowskiego 17 St, 80-214 Gdańsk, Poland
| | - Anna J Żaczek
- Department of Medical Biotechnology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of GdańskDębinki 1 St, 80-211 Gdańsk, Poland
- Innovation Synergy FoundationDragana 20/6, 80-807 Gdańsk, Poland
| |
Collapse
|
14
|
Lapińska-Szumczyk S, Supernat A, Żaczek AJ, Majewska H, Gulczyński J, Sawicki S, Biernat W, Wydra D. [Endometrial cancer in young women--clinical and molecular aspects]. Ginekol Pol 2014; 85:754-759. [PMID: 25546926] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023] Open
Abstract
OBJECTIVES The aim the study was to compare two groups of endometrial cancer patients (below and above 45 years of age) in the aspect of clinicopathological and molecular data. MATERIAL AND METHODS The study encompassed 456 primary tumour samples retrospectively collected from a cohort of endometrial cancer patients, primarily treated by surgery Molecular analysis covered: copy number variations of 10 genes (TOP2A, ERBB1, ERBB2, ERBB3, ERBB4, MYC, CCND1, ESR1, PIK3CA, RAD21) analyzed by quantitative PCR; mRNA expression of 6 genes (SCGB2A2, RAD27, RUNX1, SNAI1, SNAI2, PROM1) analyzed with the use of reverse transcription quantitative PCR; protein expression analysis of 8 markers (PGR, ESR1; ERBB1, ERBB2, ERBB3, ERBB4, TOP2A, pAKT1) performed with the use of immunohistochemistry. RESULTS The younger group of patients was characterized by less frequent hypertension (p <0.00007), less frequent myometrial infiltration (p=0.002) and longer overall survival (p=0.003). Apart from RAD21 gene aberrations, which were more frequent in younger patients (p=0.02), the study revealed no statistically significant differences between the groups. CONCLUSIONS The study showed no molecular differences in the profile of younger and older endometrial cancer patients. Data on both the prognostic and predictive significance of RAD21 in endometrial cancer are still insufficient. The clinical profile of younger patients with endometrial carcinoma was slightly better when compared to elderly patients. Younger patients were characterized by longer overall survival.
Collapse
|
15
|
Lapińska-Szumczyk S, Supernat A, Majewska H, Gulczyński J, Luczak A, Biernat W, Wydra D, Zaczek AJ. HER2-positive endometrial cancer subtype carries poor prognosis. Clin Transl Sci 2014; 7:482-8. [PMID: 25201050 DOI: 10.1111/cts.12207] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Endometrial cancer (EC) is a hormone-dependent, most frequent malignancy of the female genital tract, yet no molecular subtype classification based receptor status (estrogen receptor [ER], progesterone receptor [PR], human epidermal growth factor receptor 2 [HER2]) has been established so far. Assuming that molecular subtypes might differ fundamentally in EC, we analyzed expression levels of ER, PR, and HER2 with immunohistochemistry and aimed to determine clinical significance of four molecular subtypes: ER+/PR+/HER2+; ER+/PR+/HER2-, ER-/PR-/HER2+, and ER-/PR-/HER2-. The study included 400 formalin-fixed paraffin-embedded primary tumor EC samples which covered all stages of endometrial carcinoma, from IA to IVB. ER-/PR-/HER2+ subtype correlated with the poorest outcome, ER+/PR+/HER2- subtype was associated with the most favorable prognosis (p = 0.002). Molecular subtype division remained an independent prognostic factor in multivariate analysis, accompanying parameters such as diabetes, hypertension, stage, myometrial infiltration, and metastases, all of which yielded hazard ratios between 1.39 and 2.23. ER+/PR+/HER2+ and ER+/PR+/HER2- subtypes had low average TP53 and TOP2A expression levels when compared with ER-/PR-/HER2+ and ER-/PR-/HER2- (both p < 0.00001). Molecular subtypes in EC do show diversity in terms of prognosis, clinicopathological, and molecular characteristics. ER-/PR-/HER2+ subtype exhibit is exceptionally aggressive tumor characteristics. Subtype differentiation might aid prediction of treatment response in EC.
Collapse
Affiliation(s)
- Sylwia Lapińska-Szumczyk
- Department of Medical Biotechnology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, Gdańsk, Poland
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Supernat A, Lapińska-Szumczyk S, Majewska H, Gulczyński J, Biernat W, Wydra D, Zaczek AJ. Tumor heterogeneity at protein level as an independent prognostic factor in endometrial cancer. Transl Oncol 2014; 7:613-9. [PMID: 25048628 PMCID: PMC4225657 DOI: 10.1016/j.tranon.2014.06.001] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2014] [Revised: 06/19/2014] [Accepted: 06/23/2014] [Indexed: 12/17/2022] Open
Abstract
Intratumor heterogeneity implies heterogeneous protein function, facilitating tumor adaptation which results in therapeutic failure. We hypothesized that tumor heterogeneity at protein level may influence the course of the disease. As a single biopsy might not represent the full biologic complexity of the tumor, we have analyzed immunohistochemically four different cores obtained from each primary tumor within the cohort of 364 patients with endometrial cancer (EC). The following proteins were examined: estrogen receptor 1 (ESR1), progesterone receptor, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, receptor tyrosine-protein kinase erbB-3, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 4, phosphatidylinositol-4,5-bisphosphate 3-kinase, phosphorylated v-akt murine thymoma viral oncogene homolog 1, v-myc avian myelocytomatosis viral oncogene homolog, DNA topoisomerase II alpha 170 kDa (TOP2A), cyclin-dependent kinase inhibitor 2A (CDKN2A), tumor protein p53, RAD21 homolog, S. pombe, and runt-related transcription factor 1. Particularly strong correlation was found between TOP2A and CDKN2A heterogeneity and higher stage of the disease (P = .0002 and P = .0003, respectively). Most correlations with clinicopathologic data were observed for ESR1 heterogeneity that correlated with non-endometrioid carcinomas (P=.02), higher stage (P=.005), grade (P=.01), and the presence of metastases (P = .01). Thirty-nine (11.0%) patients were classified as “globally heterogeneous”. Cumulative tumor heterogeneity strongly correlated with the presence of metastases, higher stage, and higher grade of the disease (all P b .05). It also carried negative prognostic value (P=.0008). We show that the degree of heterogeneity in EC might serve as a clinically valid molecular marker.
Collapse
Affiliation(s)
- Anna Supernat
- Department of Medical Biotechnology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, 80-211 Gdańsk, Poland
| | - Sylwia Lapińska-Szumczyk
- Department of Gynaecology, Gynaecological Oncology and Gynaecological Endocrinology, Medical University of Gdańsk, 80-402 Gdańsk, Poland
| | - Hanna Majewska
- Department of Pathomorphology, Medical University of Gdańsk, 80-214 Gdańsk, Poland
| | - Jacek Gulczyński
- Department of Pathology and Neuropathology, Medical University of Gdańsk, 80-211 Gdańsk, Poland
| | - Wojciech Biernat
- Department of Pathomorphology, Medical University of Gdańsk, 80-214 Gdańsk, Poland
| | - Dariusz Wydra
- Department of Gynaecology, Gynaecological Oncology and Gynaecological Endocrinology, Medical University of Gdańsk, 80-402 Gdańsk, Poland
| | - Anna J Zaczek
- Department of Medical Biotechnology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, 80-211 Gdańsk, Poland.
| |
Collapse
|
17
|
Supernat AM, Lapinska-Szumczyk S, Majewska H, Gulczynski J, Biernat W, Wydra D, Zaczek AJ. Prognostic value of dysregulated ErbB signaling network in endometrial cancer. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.e16540] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Sylwia Lapinska-Szumczyk
- Department of Gynaecology, Gynaecological Oncology and Gynaecological Endocrinology, Medical University of Gdansk, Gdansk, Poland
| | - Hanna Majewska
- Department of Pathomorphology, Medical University of Gdansk, Gdansk, Poland
| | - Jacek Gulczynski
- Department of Pathology and Neuropathology, Medical University of Gdansk, Gdansk, Poland
| | - Wojciech Biernat
- Department of Pathomorphology, Medical University of Gdansk, Gdansk, Poland
| | - Dariusz Wydra
- Department of Gynaecology, Gynaecological Oncology and Gynaecological Endocrinology, Medical University of Gdansk, Gdansk, Poland
| | - Anna Joanna Zaczek
- Department of Medical Biotechnology, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Gdansk, Poland
| |
Collapse
|
18
|
Supernat AM, Lapinska-Szumczyk S, Majewska H, Gulczynski J, Biernat W, Wydra D, Zaczek AJ. Tumor heterogeneity on a protein level in endometrial cancer. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.e16539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Sylwia Lapinska-Szumczyk
- Department of Gynaecology, Gynaecological Oncology and Gynaecological Endocrinology, Medical University of Gdansk, Gdansk, Poland
| | - Hanna Majewska
- Department of Pathomorphology, Medical University of Gdansk, Gdansk, Poland
| | - Jacek Gulczynski
- Department of Pathology and Neuropathology, Medical University of Gdansk, Gdansk, Poland
| | - Wojciech Biernat
- Department of Pathomorphology, Medical University of Gdansk, Gdansk, Poland
| | - Dariusz Wydra
- Department of Gynaecology, Gynaecological Oncology and Gynaecological Endocrinology, Medical University of Gdansk, Gdansk, Poland
| | - Anna Joanna Zaczek
- Department of Medical Biotechnology, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Gdansk, Poland
| |
Collapse
|
19
|
Supernat A, Łapińska-Szumczyk S, Majewska H, Gulczyński J, Biernat W, Wydra D, Zaczek AJ. A multimarker qPCR platform for the characterisation of endometrial cancer. Oncol Rep 2013; 31:1003-13. [PMID: 24337234 DOI: 10.3892/or.2013.2924] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2013] [Accepted: 11/20/2013] [Indexed: 11/06/2022] Open
Abstract
The molecular background of endometrial cancer (EC) has not been fully elucidated. In the present study, we developed a quantitative PCR (qPCR) platform to examine the gene dosages of the potential molecular markers MGB1, TOP2A, ERBB1-4, MYC, CCND1, ESR1 and PI3K. The platform was applied in samples collected from 157 EC patients (stage I-IV) to verify its clinical utility and to examine the diagnostic and prognostic significance of the analysed biomarkers. The gene dosage pattern of the ERBB family and its downstream effectors PI3K and MYC showed particularly strong correlations with clinicopathological data. The ERBB PI3K/Akt pathway was upregulated in 31 (20%) of 156 cases. Activation of the ERBB PI3K/Akt pathway was positively correlated with a higher stage (p=0.001), higher grade (p=0.001), histological type II disease (p=0.0003) and metastases (p=0.02). The implemented hierarchical clustering revealed that cluster 2 was characterised by high copy numbers of the studied genes. Cluster 2 was associated with shorter overall survival (p=0.05). The platform was found to be a fast and simple method for direct analysis of the genes involved in uterine carcinogenesis, making it feasible for EC biology characterisation.
Collapse
Affiliation(s)
- Anna Supernat
- Department of Medical Biotechnology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, Dębinki 1, 80-211 Gdańsk, Poland
| | - Sylwia Łapińska-Szumczyk
- Department of Gynaecology, Gynaecological Oncology and Gynaecological Endocrinology, Medical University of Gdańsk, Kliniczna 1a, 80-402 Gdańsk, Poland
| | - Hanna Majewska
- Department of Pathomorphology, Medical University of Gdańsk, Dębinki 7, 80-211 Gdańsk, Poland
| | - Jacek Gulczyński
- Department of Pathology and Neuropathology, Medical University of Gdańsk, Dębinki 1, 80-211 Gdańsk, Poland
| | - Wojciech Biernat
- Department of Pathomorphology, Medical University of Gdańsk, Dębinki 7, 80-211 Gdańsk, Poland
| | - Dariusz Wydra
- Department of Gynaecology, Gynaecological Oncology and Gynaecological Endocrinology, Medical University of Gdańsk, Kliniczna 1a, 80-402 Gdańsk, Poland
| | - Anna J Zaczek
- Department of Medical Biotechnology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, Dębinki 1, 80-211 Gdańsk, Poland
| |
Collapse
|
20
|
Supernat A, Lapinska-Szumczyk S, Majewska H, Gulczynski J, Biernat W, Wydra D, Zaczek AJ. Epithelial-mesenchymal transition and cancer stem cells in endometrial cancer. Anticancer Res 2013; 33:5461-5469. [PMID: 24324082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
BACKGROUND/AIM Epithelial-mesenchymal transition (EMT) and cancer stem cells (CSCs) are presumed to be key conditions for malignancy. Data concerning their role in endometrial cancer (EC) are scarce. We aimed to investigate the possible link between EMT and CSCs markers in EC samples. MATERIALS AND METHODS The study encompassed 156 primary tumour samples. Using RT-qPCR, we analyzed the expression of EMT-related genes, SNAIL and SLUG, and the CSCs marker CD133. RESULTS SNAIL and SLUG correlated with each other (R=0.33; p=0.00003). All the studied genes were expressed in both normal and malignant endometrial tissue. Decreased SNAIL expression was found to correlate with post-menopausal status (p=0.002). Decreased SLUG expression was associated with shorter overall survival (p=0.01). CONCLUSION SLUG expression could serve as a prognostic factor in EC. No correlation between the expression of EMT and CSCs markers was found, suggesting there to be no association between the EMT and CSC phenotype in endometrial cancer.
Collapse
Affiliation(s)
- Anna Supernat
- Laboratory of Cell Biology, Department of Medical Biotechnology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, Dębinki 1, 80-211 Gdańsk, Poland.
| | | | | | | | | | | | | |
Collapse
|
21
|
Sosińska-Mielcarek K, Duchnowska R, Winczura P, Badzio A, Majewska H, Lakomy J, Pęksa R, Pieczyńska B, Radecka B, Dębska S, Biernat W, Jassem J. Immunohistochemical prediction of brain metastases in patients with advanced breast cancer: the role of Rad51. Breast 2013; 22:1178-83. [PMID: 24060578 DOI: 10.1016/j.breast.2013.08.011] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2013] [Revised: 07/06/2013] [Accepted: 08/30/2013] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND There are no clinically useful biomarkers predictive of brain metastases (BM) in breast cancer. In this study, we investigated the correlation between expression of selected proteins in the primary tumor and the risk of BM in patients with metastatic breast cancer (MBC). METHODS The study included 198 MBC patients (96 with and 102 without BM). Using tissue microarrays derived from the primary tumor, we assessed by immunohistochemical expression of ER, PR, HER2, Ki-67, CK5/6, EGFR, HER3, CXCR4, Rad51, E-cadherin, and claudin 3 and 4. RESULTS Ki-67 ≥14% (hazard ratio [HR] 2.76; P < 0.001), cytoplasmic expression of Rad51 (HR 1.87; P = 0.014) and ER-negativity (HR 1.72; P = 0.029) were associated with increased risk of BM in the multivariate analysis. A three-biomarker profile including ER, Ki-67 and Rad51 vs. other subtypes combined yielded an HR of 4.43 (P < 0.001). CONCLUSIONS ER-negativity, cytoplasmic expression of Rad51 and high Ki-67 are associated with increased risk of BM.
Collapse
|
22
|
Sosinska-Mielcarek K, Winczura P, Duchnowska R, Badzio A, Majewska H, Lakomy J, Peksa R, Pieczynska B, Radecka B, Debska S, Zok J, Rogowski W, Strzelecka M, Kulma-Kreft M, Blaszczyk P, Litwiniuk M, Jesien-Lewandowicz E, Rutkowski T, Jaworska-Jankowska M, Adamowicz K, Foszczynska-Kloda M, Biernat W, Jassem J. Abstract P3-12-09: The risk of brain metastases according to expression of selected immunohistochemical markers in primary breast cancers. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p3-12-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: About 10–30% of breast cancer patients will develop brain metastases.
In untreated patients with brain metastases the median survival is 1–2 months, and in those undergoing palliative radiotherapy — 3–6 months. The mechanism of brain metastases remains largely unknown. The identification of molecular markers might help in selecting high risk patients, and enable active surveillance, prevention and early treatment. The aim of this study was to analyze predictive value of expression of selected tumor proteins for the risk of brain metastases in breast cancer patients.
Material and methods: This study included 198 advanced breast cancer patients treated between 2001 and 2007 in 11 oncology centers in Poland, including 96 woman with and 102 without overt brain metastases, respectively. The median age at diagnosis in these two groups was 52 and 60 years, respectively, with 52% and 32% of patients being premenopausal. Stage at diagnosis was similar in both groups and ductal carcinoma was a dominant histological type (76% and 86% of cases, respectively). Immunohistochemistry was performed on formalin-fixed paraffin embedded microarray cores derived from the primary tumor. Expression analysis included ER, PR, HER2, Ki67, CK5/6, EGFR, HER3, CXCR4, RAD51, E-cadherin, and claudin 3 and 4. Cox regression model was used to estimate the relative risk of brain metastases.
Results: Expression of HER2, CK5/6, EGFR, RAD51 (both cytoplasmatic and nuclear staining), CXCR4 (cytoplasmatic staining) and Ki67 ≥14%, as well as ER or PR negativity was associated with increased risk of brain metastases in the univariate analysis (Table 1). Of those, Ki67 ≥14% (HR 2.76 [95%CI 1.70–4.48]; p < 0.001), cytoplasmatic expression of double strand DNA repair gene RAD51 (HR 1.87 [95%CI 1.14–3.08]; p = 0.014) and ER negativity (HR 1.72 [95%CI 0.36–0.94]; p = 0.029) were found to be significantly related to the risk of brain relapse in the multivariate analysis. Four molecular profiles composed of the latter three markers were created, of which a profile including ER, Ki67 and RAD51 was associated with the highest risk of brain metastases (HR 4.43 [95%CI 2.69–7.27]; p < 0.001). Molecular subtype analysis showed the highest risk of BM in the ER/PR/ HER2-negative (triple negative) subset (HR 1.21 [95%CI 1.11–1.32]; p < 0.001).
Conclusion: Expression of proteins related to high tumor proliferation, DNA repair and ER negativity is associated with increased risk of brain metastases in breast cancer patients.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-12-09.
Collapse
Affiliation(s)
- K Sosinska-Mielcarek
- Regional Oncology Center, Gdansk, Poland; Medical University of Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Regional Oncology Center in Opole, Opole, Poland; Medical University of Lódz, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; PCK Marine Hospital, Gdynia, Poland; Oncology Center in Bydgoszcz, Poland; Medical University of Poznan, Poland; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Regional Hospital in Wroclaw, Wroclaw, Poland; Pomeranian Oncology Center, Szczecin, Poland
| | - P Winczura
- Regional Oncology Center, Gdansk, Poland; Medical University of Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Regional Oncology Center in Opole, Opole, Poland; Medical University of Lódz, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; PCK Marine Hospital, Gdynia, Poland; Oncology Center in Bydgoszcz, Poland; Medical University of Poznan, Poland; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Regional Hospital in Wroclaw, Wroclaw, Poland; Pomeranian Oncology Center, Szczecin, Poland
| | - R Duchnowska
- Regional Oncology Center, Gdansk, Poland; Medical University of Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Regional Oncology Center in Opole, Opole, Poland; Medical University of Lódz, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; PCK Marine Hospital, Gdynia, Poland; Oncology Center in Bydgoszcz, Poland; Medical University of Poznan, Poland; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Regional Hospital in Wroclaw, Wroclaw, Poland; Pomeranian Oncology Center, Szczecin, Poland
| | - A Badzio
- Regional Oncology Center, Gdansk, Poland; Medical University of Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Regional Oncology Center in Opole, Opole, Poland; Medical University of Lódz, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; PCK Marine Hospital, Gdynia, Poland; Oncology Center in Bydgoszcz, Poland; Medical University of Poznan, Poland; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Regional Hospital in Wroclaw, Wroclaw, Poland; Pomeranian Oncology Center, Szczecin, Poland
| | - H Majewska
- Regional Oncology Center, Gdansk, Poland; Medical University of Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Regional Oncology Center in Opole, Opole, Poland; Medical University of Lódz, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; PCK Marine Hospital, Gdynia, Poland; Oncology Center in Bydgoszcz, Poland; Medical University of Poznan, Poland; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Regional Hospital in Wroclaw, Wroclaw, Poland; Pomeranian Oncology Center, Szczecin, Poland
| | - J Lakomy
- Regional Oncology Center, Gdansk, Poland; Medical University of Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Regional Oncology Center in Opole, Opole, Poland; Medical University of Lódz, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; PCK Marine Hospital, Gdynia, Poland; Oncology Center in Bydgoszcz, Poland; Medical University of Poznan, Poland; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Regional Hospital in Wroclaw, Wroclaw, Poland; Pomeranian Oncology Center, Szczecin, Poland
| | - R Peksa
- Regional Oncology Center, Gdansk, Poland; Medical University of Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Regional Oncology Center in Opole, Opole, Poland; Medical University of Lódz, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; PCK Marine Hospital, Gdynia, Poland; Oncology Center in Bydgoszcz, Poland; Medical University of Poznan, Poland; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Regional Hospital in Wroclaw, Wroclaw, Poland; Pomeranian Oncology Center, Szczecin, Poland
| | - B Pieczynska
- Regional Oncology Center, Gdansk, Poland; Medical University of Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Regional Oncology Center in Opole, Opole, Poland; Medical University of Lódz, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; PCK Marine Hospital, Gdynia, Poland; Oncology Center in Bydgoszcz, Poland; Medical University of Poznan, Poland; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Regional Hospital in Wroclaw, Wroclaw, Poland; Pomeranian Oncology Center, Szczecin, Poland
| | - B Radecka
- Regional Oncology Center, Gdansk, Poland; Medical University of Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Regional Oncology Center in Opole, Opole, Poland; Medical University of Lódz, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; PCK Marine Hospital, Gdynia, Poland; Oncology Center in Bydgoszcz, Poland; Medical University of Poznan, Poland; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Regional Hospital in Wroclaw, Wroclaw, Poland; Pomeranian Oncology Center, Szczecin, Poland
| | - S Debska
- Regional Oncology Center, Gdansk, Poland; Medical University of Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Regional Oncology Center in Opole, Opole, Poland; Medical University of Lódz, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; PCK Marine Hospital, Gdynia, Poland; Oncology Center in Bydgoszcz, Poland; Medical University of Poznan, Poland; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Regional Hospital in Wroclaw, Wroclaw, Poland; Pomeranian Oncology Center, Szczecin, Poland
| | - J Zok
- Regional Oncology Center, Gdansk, Poland; Medical University of Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Regional Oncology Center in Opole, Opole, Poland; Medical University of Lódz, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; PCK Marine Hospital, Gdynia, Poland; Oncology Center in Bydgoszcz, Poland; Medical University of Poznan, Poland; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Regional Hospital in Wroclaw, Wroclaw, Poland; Pomeranian Oncology Center, Szczecin, Poland
| | - W Rogowski
- Regional Oncology Center, Gdansk, Poland; Medical University of Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Regional Oncology Center in Opole, Opole, Poland; Medical University of Lódz, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; PCK Marine Hospital, Gdynia, Poland; Oncology Center in Bydgoszcz, Poland; Medical University of Poznan, Poland; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Regional Hospital in Wroclaw, Wroclaw, Poland; Pomeranian Oncology Center, Szczecin, Poland
| | - M Strzelecka
- Regional Oncology Center, Gdansk, Poland; Medical University of Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Regional Oncology Center in Opole, Opole, Poland; Medical University of Lódz, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; PCK Marine Hospital, Gdynia, Poland; Oncology Center in Bydgoszcz, Poland; Medical University of Poznan, Poland; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Regional Hospital in Wroclaw, Wroclaw, Poland; Pomeranian Oncology Center, Szczecin, Poland
| | - M Kulma-Kreft
- Regional Oncology Center, Gdansk, Poland; Medical University of Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Regional Oncology Center in Opole, Opole, Poland; Medical University of Lódz, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; PCK Marine Hospital, Gdynia, Poland; Oncology Center in Bydgoszcz, Poland; Medical University of Poznan, Poland; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Regional Hospital in Wroclaw, Wroclaw, Poland; Pomeranian Oncology Center, Szczecin, Poland
| | - P Blaszczyk
- Regional Oncology Center, Gdansk, Poland; Medical University of Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Regional Oncology Center in Opole, Opole, Poland; Medical University of Lódz, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; PCK Marine Hospital, Gdynia, Poland; Oncology Center in Bydgoszcz, Poland; Medical University of Poznan, Poland; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Regional Hospital in Wroclaw, Wroclaw, Poland; Pomeranian Oncology Center, Szczecin, Poland
| | - M Litwiniuk
- Regional Oncology Center, Gdansk, Poland; Medical University of Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Regional Oncology Center in Opole, Opole, Poland; Medical University of Lódz, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; PCK Marine Hospital, Gdynia, Poland; Oncology Center in Bydgoszcz, Poland; Medical University of Poznan, Poland; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Regional Hospital in Wroclaw, Wroclaw, Poland; Pomeranian Oncology Center, Szczecin, Poland
| | - E Jesien-Lewandowicz
- Regional Oncology Center, Gdansk, Poland; Medical University of Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Regional Oncology Center in Opole, Opole, Poland; Medical University of Lódz, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; PCK Marine Hospital, Gdynia, Poland; Oncology Center in Bydgoszcz, Poland; Medical University of Poznan, Poland; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Regional Hospital in Wroclaw, Wroclaw, Poland; Pomeranian Oncology Center, Szczecin, Poland
| | - T Rutkowski
- Regional Oncology Center, Gdansk, Poland; Medical University of Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Regional Oncology Center in Opole, Opole, Poland; Medical University of Lódz, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; PCK Marine Hospital, Gdynia, Poland; Oncology Center in Bydgoszcz, Poland; Medical University of Poznan, Poland; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Regional Hospital in Wroclaw, Wroclaw, Poland; Pomeranian Oncology Center, Szczecin, Poland
| | - M Jaworska-Jankowska
- Regional Oncology Center, Gdansk, Poland; Medical University of Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Regional Oncology Center in Opole, Opole, Poland; Medical University of Lódz, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; PCK Marine Hospital, Gdynia, Poland; Oncology Center in Bydgoszcz, Poland; Medical University of Poznan, Poland; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Regional Hospital in Wroclaw, Wroclaw, Poland; Pomeranian Oncology Center, Szczecin, Poland
| | - K Adamowicz
- Regional Oncology Center, Gdansk, Poland; Medical University of Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Regional Oncology Center in Opole, Opole, Poland; Medical University of Lódz, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; PCK Marine Hospital, Gdynia, Poland; Oncology Center in Bydgoszcz, Poland; Medical University of Poznan, Poland; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Regional Hospital in Wroclaw, Wroclaw, Poland; Pomeranian Oncology Center, Szczecin, Poland
| | - M Foszczynska-Kloda
- Regional Oncology Center, Gdansk, Poland; Medical University of Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Regional Oncology Center in Opole, Opole, Poland; Medical University of Lódz, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; PCK Marine Hospital, Gdynia, Poland; Oncology Center in Bydgoszcz, Poland; Medical University of Poznan, Poland; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Regional Hospital in Wroclaw, Wroclaw, Poland; Pomeranian Oncology Center, Szczecin, Poland
| | - W Biernat
- Regional Oncology Center, Gdansk, Poland; Medical University of Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Regional Oncology Center in Opole, Opole, Poland; Medical University of Lódz, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; PCK Marine Hospital, Gdynia, Poland; Oncology Center in Bydgoszcz, Poland; Medical University of Poznan, Poland; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Regional Hospital in Wroclaw, Wroclaw, Poland; Pomeranian Oncology Center, Szczecin, Poland
| | - J Jassem
- Regional Oncology Center, Gdansk, Poland; Medical University of Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Regional Oncology Center in Opole, Opole, Poland; Medical University of Lódz, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; PCK Marine Hospital, Gdynia, Poland; Oncology Center in Bydgoszcz, Poland; Medical University of Poznan, Poland; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Regional Hospital in Wroclaw, Wroclaw, Poland; Pomeranian Oncology Center, Szczecin, Poland
| |
Collapse
|
23
|
Majewska H, Biernat W. Merkel cell carcinoma. Pathological and molecular aspects of diagnosis and clinical features. POL J PATHOL 2010; 61:117-123. [PMID: 21225493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023] Open
Abstract
Merkel cell carcinoma (MCC) is an aggressive neoplasm of the skin usually developing in the elderly. The morphological and phenotypical characteristics of Merkel cell carcinoma was recently expanded by the molecular profile. The current review is a compilation of these data, which may enable better understanding of the histogenesis and potential target therapy in this rare tumour of the skin.
Collapse
Affiliation(s)
- Hanna Majewska
- Department of Neuropathology and Molecular Pathology, Medical University of Gdańsk, ul. Dębinki 7, 80-210 Gdańsk.
| | | |
Collapse
|
24
|
Dziewiȩcki C, Kolataj AM, Swiergiel AH, Majewska H, Piekarzewska A. Effects of restricted feeding on some steps of carbohydrate metabolism of young hens1. ACTA ACUST UNITED AC 2009. [DOI: 10.1111/j.1439-0396.1984.tb00823.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
25
|
Izycka-Swieszewska E, Majewska H, Szurowska E, Mazurkiewicz-Bełdzińska M, Drozyńska E. Papillary glioneuronal tumour of the precentral gyrus. Folia Neuropathol 2008; 46:158-163. [PMID: 18587711] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023] Open
Abstract
The article describes a case of a 15-year old boy after a head contusion with a five-month history of headaches and two seizure episodes. MR imaging revealed a partly solid and partly cystic cortical-subcortical tumour within the precentral gyrus with post-contrast enhancement. The patient underwent gross total resection of the lesion. Histologically the neoplasm was composed of pseudopapillary gliovascular structures surrounded by solid glioneuronal tumour areas. The expression of GFAP and nestin characterized the central parts of the tumour. Moreover the immunolabelling for synaptophysin, neurofilaments, Olig2 and NCAM was present in the peripheral part of the lesion. The neoplasm was consistent with a papillary glioneuronal tumour - one of the new entities in the last WHO CNS tumour classification.
Collapse
|
26
|
Majewska H, Konecka AM, Witowski A. The effect of repeated administration of L-thyroxine on the activity of certain enzymes in the blood plasma of hens. Exp Clin Endocrinol 1983; 82:320-4. [PMID: 6686147 DOI: 10.1055/s-0029-1210292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Studies on the influence of long-lasting hyperthyroidism on enzyme activities and total protein level in the blood plasma of adult Leghorn hens showed that: 1. Protein level during whole experimental period showed inconsiderable variability irrespective of T4 dose. 2. Activity of aspartate aminotransferase (GOT) and alanine aminotransferase (GPT) increased. Changes were dependent on T4 dosage level. 3. T4 had no effect on activity of aldolase.
Collapse
|
27
|
Konecka AM, Majewska H. Effect of L-thyroxine on metabolism in Japanese quails (Cotournix cotournix japonica)--II. Activity of GOT and GPT in liver, LDH and ICDH in heart and kidney after multiple injections of L-thyroxine. Comp Biochem Physiol B 1982; 73:693-5. [PMID: 7151409 DOI: 10.1016/0305-0491(82)90098-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
1. Quails hatched from eggs incubated at physiological temperature (37.5 degrees C--normal quails) and elevated (39.3 degrees C--warm quails) were injected with L-thyroxine (T4) at the dose of 600 micrograms/kg of body weight, every 48 hr for 17 days. 2. Twenty-four hours after the last injection activity of aspartate aminotransferase (GOT), alanine aminotransferase (GPT) was determined in liver homogenates and lactate dehydrogenase and isocitrate dehydrogenase in homogenates of heart and kidney. 3. Significant increase of the activity of GPT in liver homogenates was observed in normal and warm quails up to 252.9 and 186.8% of control, respectively). 4. The activity of aspartate aminotransferase increased significantly in liver homogenates of T4-treated normal quails, while such changes in the warm quails were not observed. 5. Activities of lactate dehydrogenase (LDH) and isocitrate dehydrogenase (ICDH) in heart and kidney homogenates in both T4-treated groups of birds did not change.
Collapse
|
28
|
Konecka AM, Majewska H. Effect of l-thyroxine on metabolism in Japanese quails (Cotournix cotournix japonica)—I. glycolytic enzymes activity in liver after multiple injections of l-thyroxine. ACTA ACUST UNITED AC 1981. [DOI: 10.1016/0305-0491(81)90248-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
29
|
Majewska H, Konecka AM, Witowski A. Responses upon multiple administration of L-thyroxine in hens. Theor Appl Genet 1979; 54:121-128. [PMID: 24310288 DOI: 10.1007/bf01159466] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/24/1978] [Indexed: 06/02/2023]
Abstract
Studies on the influence of repeated injections of L-thyroxine on enzyme activity and total protein level in the blood plasma of White Rock and Sussex hens have shown that: 1. The total protein level in both races decreased significantly. 2. Activity of aldolase increased in White Rock hens while in Sussex hens it increased considerably only after the last injection. 3. Activity of alanine aminotransferase did not change in White Rock hens and increased in the blood plasma of Sussex hens. 4. In both races, the activity of aspartate aminotransferase increased initially and changed after L-thyroxine injection. 5. Activity of alkaline phosphatase increased in White Rock hens, while in Sussex hens it decreased. 6. Statistically significant differences between activities of examined enzymes in both races after L-thyroxine administration were found.
Collapse
Affiliation(s)
- H Majewska
- Institute of Genetics and Animal Breeding, Polish Academy of Sciences, Jastrzebiec, Poland
| | | | | |
Collapse
|
30
|
Majewska H, Kołątaj A. The activity of aldolase, aspartate aminotransferase and the level of glucose in the blood plasma of chickens of various breeds and crossbreds. Theor Appl Genet 1978; 53:151-156. [PMID: 24309593 DOI: 10.1007/bf00273575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/27/1978] [Indexed: 06/02/2023]
Abstract
Studies on the activity of aldolase, aspartate aminotransferase and on the level of glucose in the blood serum of chickens from various breeds and crossbreds have shown that: 1. Breed and sex had a significant influence on the level of glucose and the activity of aldolase and aspartate aminotransferase. 2. The highest level of glucose was observed in both sexes of White Rock chickens; the lowest in Greenleg hens and Leghorn cocks. 3. The highest activity of aldolase was observed in White Rock cocks and Plymouth Rock hens; the lowest in Greenleg hens and Leghorn cocks. 4. The highest activity of aspartate aminotransferase was observed in White Rock chickens; the lowest in Leghorns. 5. As regards the traits investigated, crossbreds, in comparison to the parental breeds, were characterised in a majority of cases by values intermediate or only slightly different. Cases of homosis and heterosis in the level of the physiological indicators examined were also observed.
Collapse
Affiliation(s)
- H Majewska
- Department of Physiological Traits Inheritance, Institute of Genetics and Animal Breeding, Jastrzębiec, Poland
| | | |
Collapse
|
31
|
Majewska H, Kołataj A. The activity of lactate and malate dehydrogenases in the blood serum of chickens of various breeds and crossbreds. Theor Appl Genet 1977; 51:61-64. [PMID: 24317596 DOI: 10.1007/bf00299478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/07/1977] [Indexed: 06/02/2023]
Abstract
Studies on the activity of lactate and malate dehydrogenases in the blood serum of 'Leghorn', 'Greenleg' and 'White Rock' chickens and their crossbreds have shown that: 1. The highest activity of both enzymes occurs in 'Greenleg' chicken, and the lowest in the 'Leghorn' birds. 2. The mean activity of both enzymes in crossbreds was considerably higher than that obtained for the control, purebred birds. 3. The mean activity of both enzymes was higher for crossbreds than for the whole population.
Collapse
Affiliation(s)
- H Majewska
- Department of Physiological Traits Inheritance, Institute of Genetics and Animal Breeding, Jastrzebiec, Poland
| | | |
Collapse
|
32
|
Majewski C, Szulc H, Majewska H. [Reaction for acid mucopolysaccharides in the connective tissue around tumors and in the kidneys of rats with transplantable Guerin epithelioma]. Patol Pol 1966; 17:287-94. [PMID: 4224573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
33
|
Majewska H, Majewski C, Andrzejewski S. [Attempts at using Hale's reaction to detect acid mucopolysaccharides with the electron microscope]. Patol Pol 1966; 17:295-300. [PMID: 4162690] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
34
|
Majewski C, Lorkiewicz Z, Kubiak E, Majewska H. Adenosinetriphosphatase (ATPase) in the auricular heart muscle in human patients operated upon because of acquired and congenital cardiac defects. Acta Histochem 1964; 19:280-4. [PMID: 4220523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|